PT  - JOURNAL ARTICLE
AU  - Pukrittayakamee, Sasithon
AU  - Jittamala, Podjanee
AU  - Watson, James A
AU  - Hanboonkunupakarn, Borimas
AU  - Leungsinsiri, Pawanrat
AU  - Poovorawan, Kittiyod
AU  - Chotivanich, Kesinee
AU  - Bancone, Germana
AU  - Chu, Cindy S
AU  - Imwong, Mallika
AU  - Day, Nicholas PJ
AU  - Taylor, Walter RJ
AU  - White, Nicholas J
TI  - Pharmacometric assessment of primaquine induced haemolysis in glucose-6-phosphate dehydrogenase deficiency
AID  - 10.1101/2023.02.24.23286398
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.02.24.23286398
4099  - http://medrxiv.org/content/early/2023/09/20/2023.02.24.23286398.short
4100  - http://medrxiv.org/content/early/2023/09/20/2023.02.24.23286398.full
AB  - Background Primaquine is an 8-aminoquinoline antimalarial. It is the only widely available treatment to prevent relapses of Plasmodium vivax malaria. The 8-aminoquinolines cause dose dependent haemolysis in glucose-6-phosphate dehydrogenase deficient (G6PDd) individuals. G6PDd is common in malaria endemic areas but testing is often not available. As a consequence primaquine is underused.Methods We conducted a pharmacometric study to characterise the relationship between primaquine dose and haemolysis in G6PDd. The aim was to explore shorter and safer primaquine radical cure regimens compared to the currently recommended 8-weekly regimen (0.75 mg/kg once weekly), potentially obviating the need for G6PD testing. Hemizygous G6PDd healthy adult Thai and Burmese male volunteers were admitted to the Hospital for Tropical Diseases in Bangkok. In Part 1, volunteers were given ascending dose primaquine regimens whereby daily doses were increased from 7.5 mg up to 45 mg over 15 to 20 days. In Part 2, a single primaquine 45 mg dose was given.Results 24 volunteers were enrolled in Part 1, and 16 in Part 2 (13 participated in both studies). In three volunteers, the ascending dose regimen was stopped because of haemolysis (n=1) and asymptomatic increases in transaminases (n=2; one was hepatitis E positive). Otherwise the ascending regimens were well tolerated with no drug-related serious adverse events. In Part 1, the median haemoglobin concentration decline was 3.7 g/dL (range: 2.1 to 5.9; relative decline of 26% [range: 15 to 40%]). Primaquine doses up to 0.87 mg/kg/day were tolerated subsequently without clinically significant further falls in haemoglobin. In Part 2, the median haemoglobin concentration decline was 1.7 g/dL (range 0.9 to 4.1; relative fall of 12% [range: 7 to 30% decrease]). The ascending dose primaquine regimens gave 7 times more drug but resulted in only double the haemoglobin decline.Conclusions and Interpretation In patients with Southeast Asian G6PDd variants full radical cure treatment can be given in under three weeks compared with the current 8 week regimen.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialTCTR20170830002; TCTR20220317004Funding StatementUK MRC (MR/R015252/1); Wellcome (223099/Z/21/Z)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The two parts of this study were approved as separate studies. Both parts were approved by the Faculty of Tropical Medicine's Ethics Committee (MUTM 2017-036-01 and MUTM 2021-031-02) and the Oxford Tropical Research Ethics Committee (OxTREC, number 48-16). The study protocols were pre-registered on the Thai Clinical Trial Registry (TCTR, numbers TCTR20170830002 and TCTR20220317004).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced are available online at https://github.com/jwatowatson/Primaquine-Challenge https://github.com/jwatowatson/Primaquine-Challenge